As the first and only approved BCR::ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP) [24, 25, 28], asciminib is supported as a safe and tolerable long-term treatment with the potential to become the therapy of choice for patients with CML-CP. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.